OBIO®, through its Life Sciences Critical Technology and Commercialization (LSCTC) Centre for Excellence, is advancing AI innovation in critical care by supporting the implementation of the Extubation Advisor (EA) at The Ottawa Hospital (TOH). Developed by Canadian company Therapeutic Monitoring Systems Inc. (TMS), the AI-powered clinical decision support tool is designed to help intensive care unit (ICU) clinicians determine the optimal time to remove a breathing tube from patients—known as extubation. The Extubation Advisor uses real-time patient data, including vital signs and clinical history, to assess the likelihood of successful extubation and reduce the risk of complications such as respiratory failure or the need for reintubation. Its adoption at TOH followed a rigorous evaluation process that demonstrated strong performance and clinical utility. The tool has also been successfully trialed at Unity Health Toronto, further validating its effectiveness across different healthcare settings. By integrating AI into critical care workflows, the EA aims to improve patient outcomes, reduce ICU length of stay, and support clinicians with evidence-based recommendations during high-pressure decision-making moments. OBIO’s support underscores its mission to accelerate the development and real-world application of transformative health technologies in Canada. Through the LSCTC Centre for Excellence, OBIO fosters collaboration between innovators, clinicians, and healthcare institutions to bring cutting-edge solutions to patients faster. The successful deployment of the Extubation Advisor marks a significant step forward in the use of artificial intelligence to enhance clinical decision-making in intensive care, positioning Canada as a leader in AI-driven healthcare innovation.